New “more effective” shingles vaccine really useful | EUROtoday
Get real time updates directly on you device, subscribe now.
LThe High Authority for Health (HAS) has determined. From now on, it recommends the brand new vaccine in opposition to shingles, Shingrix (GSK laboratory), in two inhabitants teams, immunocompromised individuals aged 18 and over and all adults aged 65 and over, “preferentially to the Zostavax vaccine”.
Until now, the vaccine technique was based mostly completely on Zostavax (MSD laboratories). But this primary vaccine really useful for 65-74 yr olds was contraindicated in immunocompromised individuals, notably weak to shingles. Not solely does the brand new Shingrix vaccine not current this restrict, but it surely seems to be “just as safe but more effective” than its predecessor, signifies the HAS.
In actual life, Shingrix has in actual fact demonstrated “that it prevented the appearance of shingles in 79.3% of vaccinated people, while this effectiveness amounts to 45.9% for Zostavax”, maybe we will nonetheless learn within the HAS press launch. And “no statistically significant difference was noted between these vaccines regarding serious adverse events,” the Authority additional specifies.
The “awakening” of the chickenpox virus
Shingles is a blistering rash brought on by the “reawakening” of the chickenpox virus, usually contracted throughout childhood. The incidence and severity of the illness enhance with age. There are practically 10 instances per 1,000 individuals over 80 years outdated. Furthermore, shingles causes the hospitalization of two,600 individuals on common annually, 72% of whom are over 65 years outdated.
Those who suffered from it sooner or later keep in mind it for a very long time. Sometimes for all times. Shingles is first characterised by tingling and itching sensations in sure unilateral areas of the physique or face. They correspond to the territory of the lymph nodes through which the varicella-zoster virus (VZV, for varicella-zoster virus) has remained “dormant” for many years. In the acute part, shingles causes a typical blistering rash. The usually very painful disaster can then trigger continual onset of generally very painful neurological manifestations.
Good information, “the new Shingrix vaccine has also proven to be more effective in reducing post-herpetic pain (87%) than the Zostavax vaccine (66%)”, underlines the HAS.
The suggestion is just a primary step. Shingrix will then should be evaluated by the Economic Evaluation and Public Health Commission (CEESP) and the Transparency Commission to rule on its reimbursement. Currently, vaccination protection for individuals over 65 in opposition to shingles with Zostavax doesn’t exceed 5%.
https://www.lepoint.fr/sante/un-nouveau-vaccin-plus-efficace-contre-le-zona-recommande-07-03-2024-2554485_40.php